In
HIV and ID Observations, Dr. Paul Sax discusses the controversial paper published by the Cochrane Review about HCV therapy and IDSA's response to it.
A recent Cochrane Review paper addressed direct-acting antiviral therapy for hepatitis C virus in a way that, says Dr. Paul Sax, left hepatologists perplexed. In the latest HIV and ID Observations blog post, he discusses both the Cochrane paper and the IDSA response to it, which was published in Clinical Infectious Diseases.
Want to see more from NEJM Journal Watch? Register here.